Ginkgo Bioworks Holdings, Inc. $DNA Shares Sold by Cwm LLC

Cwm LLC reduced its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 7.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,374 shares of the company’s stock after selling 900 shares during the quarter. Cwm LLC’s holdings in Ginkgo Bioworks were worth $128,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. US Bancorp DE increased its position in shares of Ginkgo Bioworks by 43.5% during the 1st quarter. US Bancorp DE now owns 6,302 shares of the company’s stock worth $36,000 after purchasing an additional 1,911 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Ginkgo Bioworks by 14.4% during the 1st quarter. Bank of New York Mellon Corp now owns 26,392 shares of the company’s stock worth $150,000 after purchasing an additional 3,331 shares during the last quarter. Prescott Group Capital Management L.L.C. increased its position in shares of Ginkgo Bioworks by 1.1% during the 1st quarter. Prescott Group Capital Management L.L.C. now owns 365,717 shares of the company’s stock worth $2,085,000 after purchasing an additional 3,967 shares during the last quarter. OMERS ADMINISTRATION Corp increased its position in shares of Ginkgo Bioworks by 14.1% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 39,700 shares of the company’s stock worth $226,000 after purchasing an additional 4,900 shares during the last quarter. Finally, Swiss National Bank increased its position in shares of Ginkgo Bioworks by 11.8% during the 1st quarter. Swiss National Bank now owns 61,363 shares of the company’s stock worth $350,000 after purchasing an additional 6,500 shares during the last quarter. 78.63% of the stock is owned by institutional investors and hedge funds.

Ginkgo Bioworks Price Performance

Shares of Ginkgo Bioworks stock opened at $13.00 on Friday. The business has a 50-day moving average of $12.72 and a 200 day moving average of $10.77. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $5.00 and a 12 month high of $17.58. The stock has a market capitalization of $769.42 million, a price-to-earnings ratio of -2.22 and a beta of 1.54.

Ginkgo Bioworks (NYSE:DNA) last announced its earnings results on Thursday, August 7th. The company reported ($1.10) EPS for the quarter, beating analysts’ consensus estimates of ($1.44) by $0.34. The company had revenue of $49.60 million during the quarter, compared to analysts’ expectations of $41.60 million. Ginkgo Bioworks had a negative return on equity of 43.25% and a negative net margin of 136.56%. Ginkgo Bioworks has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on DNA shares. Cowen reissued a “buy” rating on shares of Ginkgo Bioworks in a research report on Friday, August 8th. Wall Street Zen raised Ginkgo Bioworks from a “sell” rating to a “hold” rating in a research report on Saturday, August 30th. BTIG Research raised their price objective on Ginkgo Bioworks from $6.00 to $9.00 and gave the stock a “sell” rating in a research report on Monday, August 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Ginkgo Bioworks in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus target price of $9.00.

Insider Activity

In other news, insider Steven P. Coen sold 5,609 shares of Ginkgo Bioworks stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $15.00, for a total value of $84,135.00. Following the completion of the transaction, the insider owned 5,503 shares in the company, valued at approximately $82,545. This trade represents a 50.48% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 9.72% of the company’s stock.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.